{"id":622215,"date":"2026-11-04T11:14:36","date_gmt":"2026-11-04T11:14:36","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/622215\/lowgrade-glioma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight.html"},"modified":"2026-11-04T11:14:36","modified_gmt":"2026-11-04T11:14:36","slug":"lowgrade-glioma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/622215\/lowgrade-glioma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight.html","title":{"rendered":"Low-Grade Glioma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/11\/1793806280.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Low-Grade Glioma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/11\/1793806280.jpg\" alt=\"Low-Grade Glioma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key Low-Grade Glioma Companies in the market include \u2013 Day One Biopharmaceuticals, Novartis, AnHeart Therapeutics, SpringWorks Therapeutics, Servier, Nuvation Bio, Incyte Corporation, Merck, and others.<\/div>\n<p style=\"text-align: justify\">(Albany, US), November 04, 2026 &#8211; DelveInsight&#8217;s &#8216;Low-Grade Glioma Market Insight, Epidemiology, and Market Forecast &ndash; 2034&#8217; report delivers an in-depth understanding of Low-Grade Glioma, historical and forecasted epidemiology, as well as the Low-Grade Glioma market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\"><strong>Explore the intricate details of the Low-Grade Glioma Market Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/low-grade-glioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Glioma Diagnosis and Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Low-Grade Glioma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">In May 2026, Day One Biopharmaceuticals and Servier completed patient enrollment for their pivotal Phase 3 FIREFLY-2\/LOGGIC clinical trial evaluating tovorafenib, a selective type II RAF inhibitor, as a frontline, initial monotherapy for pediatric low-grade glioma (pLGG).<\/p>\n<\/li>\n<li>\n<p>In the 7MM, the total Low-Grade Glioma market size was ~USD 990 million in 2023.<\/p>\n<\/li>\n<li>\n<p>The total Low-Grade Glioma market size in the US was estimated to be more than USD 550 million in 2023, and it is expected to grow during the forecast period.<\/p>\n<\/li>\n<li>\n<p>The total Low-Grade Glioma incident population in the 7MM was more than 9,000 in 2023.<\/p>\n<\/li>\n<li>\n<p>Among the 7MM, the US accounted for the highest number of Low-Grade Glioma incident cases in 2023, with more than 3,700 cases, and these cases are expected to increase during the forecast period. This makes the US glioma diagnosis and treatment market the largest contributor in the 7MM.<\/p>\n<\/li>\n<li>\n<p>There were no approved therapies for LGG by 2022, and the market was mainly dominated by surgery, chemotherapy, and radiation, used either alone or in combination.<\/p>\n<\/li>\n<li>\n<p>Among the second-line therapies, chemotherapy accounted for the maximum Low-Grade Glioma market share in the US in 2023.<\/p>\n<\/li>\n<li>\n<p>With upcoming therapies for LGG, the Low-Grade Glioma market size is expected to increase, giving patients drugs that can act as standard care.<\/p>\n<\/li>\n<li>\n<p>The leading Low-Grade Glioma companies include Day One Biopharmaceuticals, Novartis, AnHeart Therapeutics, SpringWorks Therapeutics, Servier, Nuvation Bio, Incyte Corporation, Merck, and others.<\/p>\n<\/li>\n<li>\n<p>Promising Low-Grade Glioma therapies include TAFINLAR + MEKINIST, OJEMDA (tovorafenib), Vorasidenib, Safusidenib (AB-218), Mirdametinib, Everolimus, Pembrolizumab + Olaparib and Temozolomide, Pemazyre (Pemigatinib), GDC-0084, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Low-Grade Glioma Market Forecast, Size &amp; Share Analysis Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/low-grade-glioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Pediatric Low Grade Gliomas Therapeutics Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Low-grade gliomas are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival compared with high-grade glioma. Because of this relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. Low-grade astrocytic tumors include diffuse astrocytoma, pilomyxoid astrocytoma, and pleomorphic xanthoastrocytoma (WHO grade II), as well as subependymal giant cell astrocytoma (SEGA) and pilocytic astrocytoma (WHO grade I tumors). IDH1 and IDH2 are the most commonly mutated genes in low-grade glioma, with mutations estimated to occur in more than 70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma and are also observed in non-pilocytic pediatric low-grade glioma, including ganglioglioma, desmoplastic infantile ganglioglioma, and approximately two-thirds of pleomorphic xanthoastrocytomas.<\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Diagnosis<\/strong><\/p>\n<p style=\"text-align: justify\">Diagnosis of LGG is made through a combination of imaging, histopathology, and molecular diagnostic methods. On computed tomography scans, LGG appears as diffuse areas of low attenuation. Conventional magnetic resonance imaging (MRI) is currently the imaging modality of choice, in which LGG is often homogeneous with low signal intensity on T1-weighted sequences and hyperintensity on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) sequences. Calcifications may be evident as areas of T2 hyperintensity\/T1 hypointensity in up to 20% of lesions, including oligodendrogliomas and astrocytomas, and are particularly suggestive of oligodendrogliomas. Glioma in general infiltrates the surrounding parenchyma despite the apparent radiographic margins observed on T2\/FLAIR sequences.<\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Incident Cases of Low-Grade Glioma<\/p>\n<\/li>\n<li>\n<p>Stage-specific Incident Cases of Low-Grade Glioma<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Incident Cases of Low-Grade Glioma<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of Low-Grade Glioma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Low-Grade Glioma Epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/low-grade-glioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">UK Glioma Diagnosis Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Epidemiology Key Findings<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The total Low-Grade Glioma incident cases in the 7MM were more than 9,000 in 2023.<\/p>\n<\/li>\n<li>\n<p>Among the 7MM, the US accounted for the highest number of Low-Grade Glioma incident cases in 2023, with more than 3,700 cases, and these cases are expected to increase during the forecast period.<\/p>\n<\/li>\n<li>\n<p>In the United States, the number of Grade 2 glioma cases was higher than Grade I glioma cases in 2023.<\/p>\n<\/li>\n<li>\n<p>Among the type-specific cases, Diffuse Astrocytoma accounted for the highest number of cases in the US, followed by Pilocytic Astrocytoma in 2023.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, Germany accounted for the highest number of Low-Grade Glioma cases, followed by France, while Spain accounted for the lowest in 2023. These trends shape the Italy glioma diagnosis treatment market and Spain glioma diagnosis treatment market within the European landscape.<\/p>\n<\/li>\n<li>\n<p>The incidence rate of mixed gliomas was stable from 2004 to 2013 and then decreased dramatically to nearly zero until 2022.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Approved Therapies for Low-Grade Glioma<\/strong><\/p>\n<p style=\"text-align: justify\">Two drugs are currently approved for Low-Grade Glioma: OJEMDA (tovorafenib) by Day One Biopharmaceuticals and TAFINLAR (dabrafenib) + MEKINIST (trametinib) by Novartis. Standard Low-Grade Glioma treatment otherwise includes surgery, chemotherapy, and radiation.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Trametinib + dabrafenib is an oral small-molecule combination that inhibits the MAPK pathway and the cell growth of various BRAF V600E-positive tumors. In June 2022, the US FDA granted accelerated approval to TAFINLAR + MEKINIST for adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>OJEMDA (tovorafenib): Day One Biopharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Tovorafenib is an oral, selective, central nervous system-penetrant, type II RAF inhibitor with activity against monomeric and dimeric forms of RAS signaling. Unlike type I BRAF inhibitors, tovorafenib does not lead to paradoxical activation of the MAPK pathway. On April 23, 2024, the US FDA granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or BRAF V600 mutation. The approval was based on results from the Phase II FIREFLY-1 trial, marking a key step for the pediatric low grade gliomas therapeutics market.<\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Pipeline Analysis<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Vorasidenib: Servier<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Vorasidenib is an investigational, oral, selective, brain-penetrant dual inhibitor of mutant IDH1 and IDH2 enzymes. It is being evaluated in the registration-enabling Phase III INDIGO study for patients with residual or recurrent Grade 2 low-grade glioma with an IDH1 or IDH2 mutation (NCT04164901). Phase I data demonstrated a median progression-free survival of 36.8 months (3.1 years) for patients with non-enhancing low-grade glioma, along with a favorable safety profile. The drug is also being evaluated in a Phase I trial for grade II\/III glioma with an IDH1 R132H mutation (NCT03343197). The US FDA accepted and granted priority review for the new drug application for vorasidenib for IDH-mutant diffuse glioma, with a PDUFA action date set for August 20, 2024.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Safusidenib\/AB-218: Nuvation Bio<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">AB-218 is a novel, potent, highly selective mutant IDH1 inhibitor with high blood-brain barrier permeability. It has demonstrated encouraging safety and efficacy signals in a Phase I trial of glioma patients, including 12 non-enhancing and 35 enhancing glioma patients. A Phase II trial has been initiated in participants with recurrent or progressive, histologically confirmed IDH1-mutant WHO Grade 2\/3 glioma, for which recruitment has not yet started. The drug was originally developed by Daiichi Sankyo, and AnHeart Therapeutics acquired it in 2020.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Mirdametinib: SpringWorks Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Mirdametinib is an oral, allosteric, brain-penetrant small molecule designed to inhibit MEK1 and MEK2, which occupy pivotal positions in the MAPK pathway. SpringWorks Therapeutics reported the initiation of a Phase I\/II clinical trial evaluating mirdametinib for the treatment of children, adolescents, and young adults with LGG.<\/p>\n<p style=\"text-align: justify\"><strong>Comparison of Emerging Drugs Under Development for Low-Grade Glioma<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Vorasidenib (Servier): Phase III; IDH1\/2 mutant low-grade glioma; oral; inhibits mutant IDH protein; small molecule.<\/p>\n<\/li>\n<li>\n<p>AB-218\/Safusidenib (Nuvation Bio): Phase II; Grade II glioma with IDH mutation; oral; IDH1 inhibitor; small molecule.<\/p>\n<\/li>\n<li>\n<p>Mirdametinib (SpringWorks Therapeutics): Phase I\/II; recurrent\/progressive low-grade glioma; oral, nasogastric tube, or gastrostomy tube; MEK1 and MEK2 inhibitor; small molecule.<\/p>\n<\/li>\n<li>\n<p>Everolimus (Novartis): Phase II; recurrent or progressive low-grade glioma in children; oral; binds to FKBP-12 and inhibits mTOR kinase activity; small molecule.<\/p>\n<\/li>\n<li>\n<p>Pembrolizumab + Olaparib and Temozolomide (Merck): Phase II; recurrent enhancing grade II and III IDH-mutated glioma; IV (pembrolizumab) and oral (olaparib); PD-1 receptor inhibition and PARP inhibition; monoclonal antibody and small molecule.<\/p>\n<\/li>\n<li>\n<p>Pemazyre (Pemigatinib) (Incyte Corporation): Phase II; glioblastoma, adult-type diffuse glioma; oral; blocks phosphorylation and signaling of FGFR1-3; small molecule.<\/p>\n<\/li>\n<li>\n<p>GDC-0084 (Kazia Therapeutics): Phase II; diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27M-mutant; oral; PI3K and mTOR inhibitor; small molecule.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab Major Low-Grade Glioma Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/low-grade-glioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Optic Nerve Glioma Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify\">The standard of care consists of maximum safe resection, the potential use of chemoradiation for high-risk patients, and lifelong radiographic surveillance, with the goal of delaying malignant transformation and maximizing quality of life. The optimal treatment of low-grade glioma, particularly its timing, is controversial, and decisions must balance the benefits of therapy against the potential for treatment-related complications. Surgery, radiation therapy, and chemotherapy may be used separately or in combination. Tumor shrinkage has been seen in selected patients using drugs or combinations such as temozolomide or the &#8220;PCV&#8221; combination (procarbazine, lomustine, and vincristine), and patients with the oligodendroglioma subtype, especially those with the chromosome 1p deletion, are most likely to benefit from chemotherapy. Many pharmaceutical companies are working to develop novel approaches to treat LGG, and with upcoming therapies the Low-Grade Glioma market size is expected to increase. This outlook applies across the broader glioma diagnosis and treatment market, including the India glioma diagnosis treatment market, South America glioma diagnosis treatment market, and GCC glioma diagnosis treatment market, as these regions follow the evolving global treatment practices.<\/p>\n<p style=\"text-align: justify\"><strong>Low-Grade Glioma Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify\">LGGs are usually treated with a combination of surgery, observation, and radiation. If the tumor is located in an area where it is safe to remove, the neurosurgeon will attempt to remove as much of it as possible. BRAF mutations have been identified as drivers of cancer growth, and BRAF V600 mutations are present in 15-20% of pediatric low-grade glioma, where they are associated with poor survival outcomes and a less favorable response to chemotherapy. Low-grade glioma is the most common pediatric brain cancer. Tovorafenib is approved for patients 6 months of age and older, whereas the previously approved TAFINLAR + MEKINIST is indicated for pediatric patients with LGG with a BRAF V600E mutation who require systemic therapy and are 1 year of age and older. DCVax-L was the sole key marketed drug involving LGG; in March 2014 it received the &#8220;Hospital Exemption&#8221; approval in Germany, and in 2018 the company transferred European manufacturing to the UK and terminated such activities in Germany.<\/p>\n<p style=\"text-align: justify\"><strong>To know more about Low-Grade Glioma Companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/low-grade-glioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Low-Grade Glioma Market Access and Reimbursement<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Low-Grade Glioma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Coverage- 7MM<\/p>\n<\/li>\n<li>\n<p>Study Period- 2022-2036<\/p>\n<\/li>\n<li>\n<p>Forecast Period- 2026-2036<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma Companies- Day One Biopharmaceuticals, Novartis, AnHeart Therapeutics, SpringWorks Therapeutics, Servier, Nuvation Bio, Incyte Corporation, Kazia Therapeutics, Merck, and others.<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma Therapies- TAFINLAR + MEKINIST, OJEMDA (tovorafenib), Vorasidenib, Safusidenib (AB-218), Mirdametinib, Everolimus, Pembrolizumab + Olaparib and Temozolomide, Pemazyre (Pemigatinib), GDC-0084, and others.<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma Market Segmentation: Total Low-Grade Glioma Market Size, Market Size by Therapies, Market Size by Class<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma Current Treatment Practices\/Algorithms and Unmet Needs<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Forecast Methodology<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma (LGG) Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview<\/p>\n<\/li>\n<li>\n<p>Treatment of Tumor<\/p>\n<\/li>\n<li>\n<p>Treatment Guidelines<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population of Low-Grade Glioma (LGG) in the 7MM<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Key Endpoints in Low-Grade Glioma<\/p>\n<\/li>\n<li>\n<p>Marketed Drugs<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>Low-Grade Glioma (LGG): 7MM Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>KOL Views<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Abhishek kumar<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lowgrade-glioma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/low-grade-glioma-market\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/low-grade-glioma-market<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lowgrade-glioma-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20262036-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Low-Grade Glioma Companies in the market include \u2013 Day One Biopharmaceuticals, Novartis, AnHeart Therapeutics, SpringWorks Therapeutics, Servier, Nuvation Bio, Incyte Corporation, Merck, and others. (Albany, US), November 04,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/622215"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=622215"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/622215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=622215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=622215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=622215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}